Why Attend
Animal Health Investment Europe is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space.
Innovation Showcase
The Innovation Showcase is a chance for emerging and pre-revenue organisations to pitch their company in front of a room of investors.
We are excited to reveal the 12 Finalists selected to present on-site this February!
Please click the "Presenter Profiles" PDF below to discover the most exciting innovations in animal health for 2018...
The Agenda
New areas of focus for 2018 include nutritional health, veterinary practice, aquaculture, diagnostics and genetics, with renowned speakers:
- GENETICS: Jonathan Lightner, Chief Scientific Officer at Genus plc
- FUTURE OF VETERINARY: Simon Innes, Chief Executive, CVS
- AQUACULTURE: Alf-Helge Aarskog, CEO, Marine Harvest
- DIAGNOSTICS: Kevin S. Wilson, CEO, Heska
- NUTRITIONAL HEALTH: Viggo Halseth, CIO, Nutreco
Download the agenda to find out more...
Animal Health Investment Europe, 2018 Agenda
Feedback from 2017
Selection Committee
Charles Hoare
Paul Dick
Julia Stephanus
Maarten Goossens
Matthias Hofer
Michael Hemprich
Ronan Molloy
Simon Mason
at London 2017
attended last year
Dragon's Den Panel
Marie-Paul Lachaud
Samer Al-Murrani
Simon Doherty
Irina Haivas
From London 2017
Advisory Board
Joachim Hasenmaier
Jishu Shi
Clinton Lewis
Dirk Ehle
Linda Rhodes
George Gunn
Aaron Schacht
Jean Deleforge
Alan Mackay
Dr. James Lloyd
ACCOMMODATION
Grange St. Paul’s Hotel
10 Godliman Street, London, EC4V 5AJ (0.6 miles from 200 Aldersgate)
To book a room please email: [email protected]
Rate per night: £286.80 includes vat & Continental breakfast.
Quote Group ID 190218B when booking
Please book by 30 January 2018
Crowne Plaza London, The City
19 New Bridge Street, London EC4V 6DB (0.8 miles from 200 Aldersgate)
To book a room please email Seraya: [email protected]
or call her on + 44 (0) 207 438 8034
Rate per night: £259.00 inc. VAT & English breakfast
Always quote ‘GA1 KISACO’ when booking
Please book by 7 January 2018
Thistle City Barbican Hotel
Monday 19th February: £155 per night inc VAT and English breakfast.
Tuesday 20th February: £170 per night inc VAT and English breakfast.
To book a room please call +44 (0) 800 330 8002 (option 2 for Groups) or email: [email protected]
Always quote 'GA1K190218' when booking
Please book by 22 Jan 2018
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Book a Team to Save More!
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
Payment Terms for Animal Health Investment Europe:
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- * Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate. *PLEASE NOTE – no additional discounts are available on ‘Emerging Company’ pricing. Partner discounts are ONLY available on ‘Industry’ pricing.
The Speakers
Aaron Schacht
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Alasdair Cook
Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change. His interest in epidemiology grew from working in farm animal veterinary practice in the UK and in preventive veterinary medicine. A decade of overseas experience in Yemen, Zambia and Mexico working with poor rural communities underlined the important role that veterinary epidemiology plays in supporting animals in sustainable livelihoods and poverty alleviation. A professional life engaged with and leading multi-disciplinary teams makes Alex a natural proponent of the One Health perspective.
Alf-Helge Aarskog
Mr. Aarskog has served as CEO of Marine Harvest since 2010. Prior to this position, he was the CEO (2009 to 2010) and Exective Vice President (2007 to 2009) at Lerøy Seafood Group ASA. His previous positions include Managing Director (2004 to 2007) of Lerøy Midnor AS, a subsidiary of Lerøy Seafood Group ASA, and Head of Production (2002 to 2004) at Fjord Seafood ASA, a company that was later merged with ours. He holds a degree in Fish Nutrition from the University of Agriculture in Norway.
Anne Chauder
Anne Chauder is the third generation at the head of a French independent family group of 350 employees, pioneer in animal health. In 2003, after studying Management, she chose to bring her skills to the family business. She became Executive Director in 2012 and then C.E.O in 2016 with aims to prepare the Dômes Pharma Group to address its third great evolution: digitalization and internationalization.
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins Universi
Carl Damiani
Former President and Chief Operating Officer of Transition Therapeutics, a NASDAQ listed human-focused biotechnology company acquired by OPKO Health in September 2016. Transition developed a Phase 2/3 Alzheimer’s disease program, a Phase 2 diabetes program and held multiple partnerships with large pharma companies. Mr. Damiani founded Simini Technologies in 2017 to develop human drug candidates as veterinary therapeutics with an initial focus on dermatology and pain management.
Clare Allen
Clare is Deputy Director of Teaching (Quality Assurance) in the Department of Veterinary Medicine at the University of Cambridge, where she oversees quality assurance of veterinary teaching in the university. She has also chaired taskforces to develop a curricular thread on professional skills and introduce pedagogical innovation through the use of learning technology throughout the professional veterinary course. Clare graduated from the University of Cambridge in 1996 and after completing an equine ambulatory internship at Millbrook Equine Practice in New York she started teaching on an equine studies programme and founded her own equine practice.
In 2005-06 Clare taught at Cornell University College of Veterinary Medicine and became interested in veterinary education and curriculum development. Clare completed her PhD in Higher Education and Student Affairs at the Ohio State University in 2013, with her doctoral research focusing on the career choice of veterinary students in the context of the feminisation of the profession.
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Erwin Blomsma
Erwin Blomsma holds a Master’s degree in Bioscience Engineering and a Ph.D. in Applied Biological Sciences (1995) from KU Leuven in Belgium. After post-doctoral studies at UCB he started his career at Janssen Pharmaceutica in 1996 with a focus on assessing and implementing new technologies. In 2000, he co-founded Crystallics, a spin-off from the University of Leiden (NL) specializing in preformulation research. Crystallics was absorbed by Avantium Technologies in 2001, and he was appointed Chief Operating Officer there in 2004, playing a key role in making the company cash-positive. In 2007, Dr Blomsma joined Dr Stefaan Wera and Professor Johan Neyts as co-founder and CEO of Okapi Sciences and after a series A of 8.5 million EUR end of 2008 the team developed a pipeline of 7 products (2 in pivotal clinical trials) and signed a license deal with Novartis Animal Health in 2013. Okapi Sciences was then acquired by Aratana Therapeutics for 44 million USD in January 2014. From the acquisition to August 2015 he was the General Manager of Aratana Therapeutics NV in Belgium and Vice President of Aratana Therapeutics, Inc. In 2015, Erwin Blomsma co-founded ViroVet. In 2016 ViroVet raised 5 million USD in a series A financing round. Erwin Blomsma is CEO at ViroVet and also the current Chairman of FlandersBio, a cluster organization representing over 350 life sciences companies in Flanders, Belgium.
George Gunn
Gudrun Ravetz
Currently Gudrun works as a Veterinary Consultant to Pet Health Plans from Denplan and as an external interviewer for prospective veterinary students at University of Liverpool. Alongside practicing as a small animal veterinary surgeon on graduating in 2002, Gudrun furthered her interest in the business side of the veterinary profession by studying for the post graduate certificate in business. Gudrun became President at the BVA Member’s Day and AGM on 22 September 2016.
Dr. Henrik Bjørn Nielsen
Irina Haivas
Irina is a healthcare specialist with a background in medicine and management consulting. She previously spent seven years with Bain & Company, where she was a leader in the European healthcare practice, and brings a wealth of experience across Europe, the US and emerging markets to the firm. Irina has advised multiple private equity funds on healthcare due diligence and post-acquisition projects, and has worked directly with pharmaceutical, biotechnology, and healthcare services companies on strategic initiatives including growth, business models, R&D and innovation, M&A, organisational development and operational improvement.
Irina is a medical doctor with a first-in-class degree and experience across multiple healthcare systems. She studied medicine at Iasi Medical University in Romania and Freiburg University in Germany as a Rotary Scholar, and was a visiting surgical fellow at Harvard Medical School. She also holds a MSc in International Health Policy from London School of Economics where she graduated with distinction. A native Romanian speaker, Irina is fluent in English and German and is conversational in French and Italian.
James M. Wilson
James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993, initially focusing on the clinical translation of existing gene transfer technologies but soon redirecting his efforts to the development of second and third generation gene transfer platforms, the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.
More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Throughout his career, the focus of Dr. Wilson's research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. He is the founder of a 501(c)3 called Health Through Fitness in Orphan Diseases and Director of a bicycle team called Rare Disease Cycling whose participants compete at a national level and help raise money for rare disease research.
Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in peer-reviewed literature and is an inventor on over 117 patents. He was the second President of the American Society of Gene Therapy, the 2014 recipient of the William Osler Patient Oriented Research Award of the University of Pennsylvania and 2015 recipient of the Scientific Achievement Award
Jenny Tooth
Jenny is CEO of the UK Business Angels Association, the trade body for angel and early-stage investing, representing over 18,000 investors around the UK. Jenny has over 20 years’ experience of facilitating SMEs’ access to investment, both in the UK and internationally. She ran her own consultancy on access to finance for SMEs, including spending nine years based in Brussels, working closely with the EC. In 2009, Jenny co-founded Angel Capital Group which incorporates London Business Angels, one of the most established and active angel networks in the UK.
Jenny is an angel investor and in her role at UKBAA she focuses on building the angel community around the UK, connecting investors to good deal flow and assisting entrepreneurs to attract investors. Jenny sits on the steering group for emerging technologies and innovations for Innovate UK and the advisory board for the London Co-Investment Fund. Jenny is an experienced speaker on angel investing and entrepreneurship both in the UK and internationally. She has an MSc in Economics from the London School of Economics and Political Science. Jenny was awarded an OBE in 2015 for services to small businesses.
Karin Hoelzer
Karin Hoelzer is a senior officer in health programs supporting Pew’s safe food and antibiotic resistance projects. Hoelzer, a veterinarian by training, focuses on research and policies related to foodborne pathogens, the use of antibiotics in animals, and other public health risks related to the food supply.
Before joining Pew, Hoelzer worked at the U.S. Food and Drug Administration, where she developed and led risk assessments and conducted systematic reviews and meta-analyses on a variety of issues, such as drug residues in dairy products and Listeria monocytogenes in retail delicatessens. Previously, she was a research associate at Cornell University, where she traced the transmission of pathogens between livestock and humans.
Hoelzer holds doctorates in veterinary medicine from the University of Veterinary Medicine in Hannover, Germany and comparative biomedical sciences from Cornell University. She has received numerous honors and awards, including a Morris Animal Foundation fellowship training grant, and is the author of many peer-reviewed publications. Hoelzer is a member of the American Veterinary Medical Association, the Society for Risk Analysis, and the International Association for Food Protection. She serves as scientific editor for the Elsevier journal Research in Veterinary Science.
Kathrin Ladetzki-Baehs
Dr. Kathrin Ladetzki-Baehs joined MorphoSys > 10 years ago as a scientist. Following several years of intense laboratory work in antibody generation as a project team leader, she became an alliance manger in 2012.
Today, Kathrin (Director at MorphoSys) coordinates multiple therapeutic antibody projects in close collaboration with international external partners at MorphoSys.
Kathrin is a pharmacist and received the PhD from Ludwig Maximilians University Munich. Two dogs are beloved family members in Kathrin’s home. As one the dogs got diagnosed with canine cancer, Kathrin came up with the idea to transfer the whole expertise and knowledge of phage display, library generation and antibody generation from MorphoSys into the veterinary field. Since then she is responsible for all activities necessary to found adivo.
Kevin S. Wilson
Kevin S. Wilson has been Chief Executive Officer and President of Heska Corporation (HSKA: NASDQ) since March 31, 2014. He previously served as President and Chief Operating Officer since February 2013. Heska is based in Loveland, Colorado, has approximately 350 employees primarily throughout North America, and is dedicated to veterinary healthcare through its companion pet and equine diagnostics (blood and imaging) business and its vaccines, pharmaceuticals, and biologics segment. Since 1992, Mr. Wilson has been involved in developing technologies for imaging devices and data management in the veterinary medical space. Mr. Wilson is a founder, member and officer of Cuattro, Cuattro Medical, and Cuattro Software. In 1996, Mr. Wilson founded Sound Technologies, Inc., a veterinary diagnostic imaging company, which was sold to VCA Antech, Inc. (WOOF) in 2004, following which Mr. Wilson served as Chief Strategy Officer for VCA Antech, Inc. until 2006. Mr. Wilson resides in Beaver Creek, Colorado with his wife of 25 years and their four children (the origin of the Cuattro name being “four”). Mr. Wilson serves and has served on the board of various private, non-profit, and educational organizations.
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Marie-Paul Lachaud
Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana’s products targeted at unmet medical needs in cats and dogs.
Prior to joining Aratana, Dr. Lachaud served the veterinary pharmaceutical industry as an experienced consultant, with a specific focus on international drug clinical development.
From 2000 to 2008, Dr. Lachaud was the European animal health director at ICON Clinical Research in Paris, France. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on drug clinical development and regulatory affairs, which was acquired by ICON in 2000.
Dr. Lachaud has been involved in transitioning human drugs to meet unmet needs in veterinary medicine for years. Her work has resulted in significant animal health product approvals in Europe and the United-States for companion animals in a number of innovative therapeutic areas, including reproduction, chronic heart failure, chronic kidney disease, pain management, oncology and neurobehavioral disorders.
She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.
Matt Dobbs
As Managing Director of Ruminant and Insight, Matt’s primary focus is on developing and improving the group’s people, services and products through providing a range of support services including training, research and consultancy. Matt has been published in several publications in the veterinary field, and has spoken at numerous conferences in the UK, USA, Europe and Australia.
Peter McCarthy
Mr. McCarthy is now in his 7th year at Henry Schein, Inc. He is currently the Company's President, Global Animal Health Group, as well as a member of Henry Schein's Executive Management Committee.
Mr. McCarthy oversees Henry Schein's animal health business, which spans 24 countries including the United States, Australia, New Zealand, Canada, China, Malaysia, Brazil and 17 countries in Europe.
Before assuming his current position, Mr. McCarthy held key roles at Henry Schein with increasing responsibilities, including President, Henry Schein Animal Health, Europe, and President, Henry Schein Animal Health, International.
Prior to joining Henry Schein, Mr. McCarthy worked at Schering-Plough Animal Health (now Merck Animal Health), serving as Senior Director, Global Operations and General Manager, China. Mr. McCarthy also worked at Wyeth/American Cyanamid for 14 years, helping to grow the human pharmaceutical business.
Mr. McCarthy holds a degree in Applied Biology from the University of Hertfordshire in the U.K., and previously has served as a Member of the Board of the International Federation for Animal Health Europe, and the International Association Executive Animal Health Study Center, CEESA, based in Belgium. Mr. McCarthy is also a graduate and member of the Chartered Institute of Marketing (CIM), which is located in the U.K.
Randolph Seidler
Sam Al-Murrani
Babylon BioConsulting LLC is a human and animal health-based consultancy firm specializing in pre-revenue and early stage valuations of Animal Health and Biotech companies and providing clients with investor outreach, due diligence, business development and intangible asset management and valuation services. Dr. Sam Al-Murrani is also Managing Director for Bimini LLC, a privately owned manufacturer of pet dose-form health supplements and health treats.
Dr. Al-Murrani has a B.Sc. in Animal Science from the University of Edinburgh and a Ph.D. in Immunology/Biochemistry from the Roslin Institute and the Department of Veterinary Pathology at the University of Edinburgh. He holds an M.B.A. in Finance from Baker University.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Simon Doherty
Simon is the Senior Vice-President of the Northern Ireland Branch of the British Veterinary Association (BVA). He is an Honorary Lecturer at Queen’s University Belfast and a trustee of livestock development charity, Send a Cow. Simon graduated from the University of Glasgow Veterinary School in 2000 and his career has spanned general veterinary practice, animal health & welfare policy, diagnostics, research, epizootic disease preparedness and biotechnology; with a specific interest in the design of novel vaccines for food-producing animals.
Simon is the Animal Science Specialist for the Agri-Tech Organisation of UK Trade & Investment (UKTI). Using his broad knowledge of the animal health sector, coupled with an understanding of the UK Agri-Tech offer, Simon works with animal health companies – from SMEs to large multinationals – to maximise their opportunities by locating in the UK. In addition to technologies linked to livestock, his portfolio also includes companion animal and aquaculture innovation.
Simon Innes
Simon was appointed as Chief Executive in January 2004. Prior to this he was Chief Executive of Vision Express from 2000 to 2004, over which time he built the business up to £220m turnover and 205 practices, and reversed a loss-making position to create one of the most profitable corporate optical operators in the UK. The growth strategy that was successful at Vision Express is now being implemented in the veterinary industry by CVS.
Prior to Vision Express, Simon was on the board of Hamleys PLC as Operations Director and gained 10 years’ management experience at Marks & Spencer. He also served seven years in the British Army, achieving the rank of Captain in the Royal Engineers.
Sorina Casian Botez
As part of the Principal Investments team, Sorina drives the strategy for Eight Roads’ real estate portfolio and works with the management teams of healthcare portfolio investments and associated food and agriculture venture fund, Anterra Capital.
Viggo Halseth
Viggo joined Nutreco in 1984. He has a longstanding career in Nutreco and had various positions in marketing, general and business unit management within Skretting ARC and Skretting. Viggo studied Animal Hubandry at Agriculture University and Marketing and Strategy Development at Norwegian Business School.
Headline Partner
Elanco
Website: http://www.elanco.com
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. We understand the powerful role healthy animals play in making lives better. We support the physical, emotional and social well-being of people thru a balanced diet rich in protein and the companionship of a pet. And, we preserve the health of the planet by helping farmers raise animals more efficiently. Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. Visit us at Elanco.com and EnoughMovement.com.
Associate Partners
Antelliq
Website: http://www.antelliq.com
Antelliq: intelligence connecting animals with people
Antelliq is the world’s leading animal intelligence group, providing world-class devices for animal identification and traceability. Our pioneering monitoring solutions deliver smart data products and services for the management and wellbeing of livestock, fish and pets.
For over 60 years we have been satisfying customer needs in over 100 countries, supported by 24 production sites, spanning five continents.
Antelliq has four regional innovation centres and many brands working collaboratively to address some of the world’s most pressing challenges:
- Supporting farmers with real-time actionable information: Through Allflex, SCR and our other livestock focused brands, our intelligence and monitoring helps farmers to manage herds and meet the world’s increasing demand for protein.
- Providing a deeper connection with pets: Through Sure Petcare, we provide pet owners with smart devices and data that give them a better understanding of their pets’ health needs and wellbeing, enriching relationships.
- Supporting conservation: Through Biomark, we help conservationists safeguard natural environments and wildlife.
Across Antelliq, our different brands provide the technology and intelligence that will be at the heart of overcoming these challenges. Antelliq is the embodiment of everything we stand for: intelligence connecting animals and people.
To discover more about our business, brands, innovation centres and where we operate, visit www.antelliq.com
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Bayer
Website: http://www.bayer.com
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
GHO Capital
Website: http://ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare private equity firm based in London. GHO Capital works with ambitious management teams of profitable businesses that have the potential to deliver a combination of double-digit top line growth, significant efficiency gains and international expansion. The Firm’s 2015 vintage fund – GHO Capital Fund I LP – has been raised to seize the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment and industry skills which sets the Firm apart from traditional private equity firms. For further information, please visit www.ghocapital.com.
Stifel
Website: http://www.stifeleurope.com
Stifel Investment Banking provides strategic advisory services to our clients in North America, Europe, and Asia that include initiating, structuring, and negotiating mergers, acquisitions, and divestitures as well as providing fairness opinions, valuation, and restructuring services. We raise public and private debt and equity for our clients through our institutional and retail brokerage network.
Our healthcare team has particular expertise in the animal health sector globally and individual members of our team have executed M&A transactions for companies including Zoetis, Virbac, Lohmann Animal Health, Pharmaq, Elanco, and Boehringer Ingelheim whilst employed at previous financial institutions. Stifel also acted as Bookrunner on the IPOs of Aratana and Trupanion. Stifel also has dedicated financial sponsors and a venture capital effort, maintaining regular dialogue and deal flow with private equity firms focused on Stifel’s core industry groups.
Stifel clients are served through Stifel, Nicolaus & Company, Incorporated in the U.S., through Stifel Nicolaus Europe Limited in the United Kingdom and Europe, and through Keefe, Bruyette & Woods, a Stifel company, in the U.S. and Europe. The combination of a full-service product offering and our bankers’ deep domain and product expertise allows us to provide solutions that meet the evolving needs of our clients.
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees.
For more information, visit www.zoetis.com.
Consulting Partner
Stonehaven Consulting
Website: http://www.stonehaven-consulting.com
Stonehaven Consulting AG was founded in 2015 as a specialist Life Science management consultancy firm. Based in Switzerland, we provide international consulting services to all sectors in Life Sciences.
We are especially interested in assisting ambitious clients wishing to commercialise new technologies or leverage opportunities for growth. We do this by following a unique approach where we not only help our clients to develop the best possible strategy but partner with them to bring it to life – we are happy to share risks and opportunities. We are an experienced group of individuals with a long track record of successful operational and strategic management on many levels and for a number of multinational Animal Health companies as well as companies in Life Sciences.
Our founder, George Gunn has served as CEO for a number of companies and our other members of the team bring complementary skills and experience to our group. All of us have substantial experience and background in Animal Health – an industry we are very excited about.
Senior Event Partner
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Event Partners
Anterra Capital
Website: http://www.anterracapital.com
We are a specialist venture capital investor dedicated to financing the growth of companies operating in the food & agricultural sectors
We invest across the food supply chain in technology driven companies
We focus on companies headquartered in Europe or North America although we will consider companies in other geographies
At the time of our investment our companies are typically generating revenue and have great growth prospects
We invest up to USD 20m in equity per company taking a significant minority ownership position
We are active in the boards of portfolio companies working alongside management teams to build lasting value
As a sector specialist we pride ourselves on our ability to add value in ways that generalist investors can't even dream of
Ceva
Website: http://www.ceva.co.uk
Ceva Santé Animale (Ceva) is one of the fastest growing top 10 veterinary healthcare companies. We research, develop and produce vaccines and pharmaceutical products for poultry, companion animals, livestock and swine.
Ceva has been directly present in China for over 15 years and is heavily invested through R&D partnerships and local production of vaccines.
Ceva Huadu, Beijing focuses on poultry vaccine production and the recently formed Ceva Ebvac, Hangzhou City, will drive the rapidly expanding swine vaccine business
Since 2011, Ceva has entered into a number of scientific cooperation agreements (South China Agricultural University (SCAU), University of Beijing) designed to share knowledge and ensure that the company’s international poultry and swine expertise can be applied to local conditions in China.
Globally, Ceva is one of the leading poultry healthcare suppliers having driven innovation in hatchery vaccination, to improve efficiency and performance. Ceva’s C.H.I.C.K programme was the first hatchery services programme to be independently approved by the international standards company, Bureau Veritas. Demonstrating the company’s commitment to help its customers to constantly enhance their productivity through different means of innovation.
In swine, the company has a balanced portfolio of vaccine and pharmaceutical products that are also supported by extensive veterinary and technical services programmes (Lung programme, Respinomics).
Our growth in China, reflects the entrepreneurial nature of Ceva, which is owned and managed by its senior management team. 40% of our growth has come from the more than 30 acquisitions and innumerable license agreements that we have made since 2000. As a result, we are always open to receiving innovation proposals to generate growth in China and beyond.
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
Highlands and Islands Enterprise
Website: http://www.hie.co.uk
Highlands and Islands Enterprise (HIE) is the Scottish Government's economic and community development agency for the north and west of Scotland, with a track record in working with growing enterprises and supporting investment in the region.
Life Sciences is a key sector for the agency’s support with animal health and aquaculture key components in the region’s expanding sector.
Tailored assistance including information, advice and funding supports business development. With a strong collaborative tradition, close links to academia and an impressive range of purpose- built Life Sciences facilities, the Highlands and Islands of Scotland offer an attractive location where businesses can grow and thrive.
IDEXX BioAnalytics
Website: http://www.idexx.co.uk
IDEXX BioAnalytics is your strategic partner for reliable, reproducible results whilst accelerating your research through innovative technologies, logistics support and scientific expertise, so you can confidently improve the health and welfare of people and animals.
IDEXX BioAnalytics is a division of IDEXX Laboratories which was founded in 1983.
In the last 15 years, IDEXX BioAnalytics scientists have been innovation leaders in laboratory animal diagnostics, publishing over 250 scientific articles and developing novel approaches to animal health monitoring such as our Opti-Spot™ blood collection methodology.
• We are your partner in progressing research
• A global market leader in diagnostics solutions for animal health, water and dairy quality
• Over 6,500 global employees
• Over 400 scientists, pathologists and veterinarians on staff
• Over 60 locations worldwide
• Over 280 million invested in R&D in the last 5 years
OCR
Website: http://www.oncovet-clinical-research.com
OCR is a full-Vet CRO based in Lille-France, with a know-how on every steps of the clinical development and registration of a product for the pets market. OCR is specialized in clinical studies on severe diseases affecting dogs and cats: cancer, and others diseases in therapeutic areas like inflammation, cardiology, dermatology, antibiotic resistance, neurology. Along with a highly experienced team (clinical project leaders, RCA, data managers, biostatisticians, and veterinary specialist consultants), OCR built a European network of veterinary clinics with high level technical platform, including imaging (CT-scan, MRI, scintigraphy) and radiation therapy units and vet specialist strongly involved in clinical research. Our expertise in a nutshell: conception of the study with vet experts, determining pre-clinical and clinical development plans, conducting Proof-of-Concept studies, Pilot and Pivotal studies, site selection, laboratory identification and management, regulatory affairs, data management & biostatistics, VICH GCP clinical studies standards. Strong track record with the vet industry with pilot/pivotal studies, as well as with biotech/pharma through comparative medicine studies.
Paul Dick and Associates (PDA)
Website: http://pauldickassociates.com
Paul Dick & Associates Ltd. (PDA), founded in 2010, is an animal health consulting firm specializing in (1) the creation of strategic business and product life plans, (2) product development and regulatory affairs strategies, (3) the conduct of GCP studies, (4) the development of white papers to support marketing and sales, (5) business development and fundraising, (6) the acquisition and pitching of new technologies, actives and products, and, (7) various other supporting activities for product development and commercialization. The capabilities of Paul Dick & Associates Ltd. span the research, development, regulatory, and, commercialization continuum for animal pharmaceuticals, biologicals, vaccines, feed ingredients and feeds, and natural/ low risk health products. PDA is the recognized expert for these matters in Canada, as well as for other global markets.
Pet Flavors
Website: http://www.petflavors.com
Pet Flavors Inc. (PF, Inc.) is the world leading developer and manufacturer of quality flavor bases for both pharmaceutical drugs and nutritional supplements in the animal health industry. PF Inc. sells several types of flavor bases for use in formulating palatable canine, feline, and equine dosage forms that are sold on a worldwide basis. PF Inc's Artificial Powdered Beef Flavor; PC-0125 is sold to 9 of the top 10 largest animal health pharmaceutical companies in the world and has been successfully formulated in over 20 New Animal Drug Approvals (NADAs). Our company has over 30 years of experience with formulation and product development. With an active ingredient and our flavor bases we can create highly palatable chewable tablets, soft chews or granules. Our services include improving the palatability of an existing product, creating product line extensions or developing entirely new products. The goal of our company is to have all pharmaceutical and nutraceutical animal health companies develop new health products with flavoring in mind. By making medications and supplements taste and smell better, we can help pet owners develop a stress free process that ensures pets are obtaining the medication and nutrition they need to live longer, healthier lives.
Phibro Animal Health Corporation
Website: http://www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
Triveritas
Website: http://www.triveritas.com
Triveritas is a veterinary CRO with local offices in Europe and North America providing assistance in the development and registration of biological and pharmaceutical products in Animal Health. With a global customer base, both start-up and Top 10 Animal Health companies count amongst returning customers. Regulatory Affairs services, from initial strategic advice to final submission of dossiers, are provided by a highly competent team, including biologicals and pharmaceuticals specialists, a toxicologist, CMC/Part II experts and Qualified Persons for Pharmacovigilance. An integrated approach to project management has lead to proven success in the approval of products at EMA, FDA, USDA and EPA. Clinical Studies, compliant to VICH GCP, are performed by fully trained, experienced Monitors, veterinarians, data managers and support scientists, together with collaborating Investigators and laboratories. Independent Quality Assurance auditors provide inspection services in VICH GCP/GLP/GMP.
Virbac
Website: https://uk.virbac.com/
Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world’s 7th largest animal health company, Virbac sells products in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation, based on both technological advances and listening to its customers, relies on reactive production facilities which meet the highest international quality standards. For nearly fifty years, these features have allowed the company to build a personalized relationship with veterinarians and farmers around the world.
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
Media Partners
Animal Pharm
Website: https://animalpharm.agribusinessintelligence.informa.com
We have been providing animal health professionals worldwide with news, analysis and insight for over 30 years, and cover the food producing animal and companion animal sectors. With extensive information on animal health products including antiparasitics, vaccines, pharmaceuticals, feed, feed additives and equipment.
Features include:
- Analysis of business and company news
- Reporting on key players in the industry
- Market developments and trends
- Analysis of the latest global regulatory changes
- News on product research and development
- Expert opinion and analysis
Pig333
Website: http://www.pig333.com
Pig333.com is a community website, which covers the entire swine sector from "pig to pork". With the collaboration of international specialists, we generate our own content from which users can debate and share ideas. We have nearly eigtheen years experience generating independent online content for the swine sector.
What does 333 mean? Those familiar with pig production will know that the gestation of the sow is approximately 3 months, 3 weeks and 3 days long, so it is a key number!
The Fish Site
Website: http://thefishsite.com
The Fish Site is a knowledge sharing platform with premium news, analysis and resources for the aquaculture and commercial fishing industries. It also publishes Sustainable Aquaculture Magazine.
Our international team of contributors are guided by our vision for aquaculture, reporting on the economics, environment and ethics of contemporary food chain challenges. We challenge the status quo to create understanding, opportunity and innovation.
The Fish Site is published by 5m Enterprises, who also host Aquaculture UK and the Scottish Marine Aquaculture Awards, deliver Sustainable Aquaculture courses in partnership with St Andrew’s University and publish a range of aquaculture titles as 5m Books.
The Poultry Site
Website: http://www.thepoultrysite.com
Please visit our website for more information.UKBAA
Website: http://www.ukbaa.org.uk
The UK Business Angels Association (UKBAA) is the national trade association for angel and early-stage investment, representing over 160 member organisations and around 18,000 investors.
Business angels in the UK collectively invest an estimated £1.5 billion per annum and are therefore the UK’s largest source of investment for startups and early-stage businesses seeking to grow.
UKBAA’s members include angel networks, syndicates, individual investors, early-stage VCs, equity crowdfunding platforms, accelerators, professional advisers and intermediaries. UKBAA acts as the voice of the angel investment community and strives to build and connect the angel investment ecosystem so as to ensure a coherent landscape for financing high-potential entrepreneurs.
Veterinary Practice
Website: http://www.veterinary-practice.com
Veterinary Practice magazine is a lively, informative and educational publication devoted solely to the issues facing veterinary practices right now.
Each month's issue features the best writers in the profession on the topics of the day, with informed comments on current challenges along with concise features.
- CPD
- employment law
- literature review
- practice design
- investments
- latest product developments
- health and safety
- nursing news
- regular signposted sections for large animal and equine
- industry and product news ... and much, much more.
Watt Global Media
Website: http://www.wattglobalmedia.com/
As an industry innovator, WATT Global Media has connected buyers and sellers in the poultry, animal feed and pet food industries through its media channels for 100 years.
NEW FOR 2018!
Kisaco Research have teamed up with Stonehaven Consulting AG to offer a FREE HALF-DAY OF CONSULTATION to each of the twelve emerging companies that will be selected to present.
Stonehaven Consulting AG are a premier consulting company that specialises in assisting ambitious clients wanting to commercialise new technologies or leverage growth opportunities. They will give one of their partners’ services to each presenting company, for a full half day ahead of the conference.
This is an excellent opportunity, with the chance for each presenting company to focus on an area of their choice; for example:
- Advice on how to select the right Business/Financing Partners
- Building and telling a story which appeals to investors
- Advice on how to improve or optimize your Animal Health Investment Europe conference presentation
- Strategic considerations pertaining your business
- and more…
Become a Sponsor
Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.